Shares of NuCana PLC (NASDAQ:NCNA) have been assigned a consensus rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $36.00.
NCNA has been the subject of a number of research reports. Zacks Investment Research upgraded NuCana from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research note on Saturday, March 30th. William Blair reiterated an “outperform” rating on shares of NuCana in a research note on Thursday, May 16th. Finally, BidaskClub cut NuCana from a “hold” rating to a “sell” rating in a research note on Wednesday.
Shares of NCNA opened at $11.94 on Wednesday. NuCana has a 52 week low of $10.37 and a 52 week high of $30.10. The firm has a market capitalization of $388.37 million, a PE ratio of -20.95 and a beta of 3.92.
NuCana (NASDAQ:NCNA) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.22) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.22). On average, sell-side analysts predict that NuCana will post -1.14 earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in NCNA. Alps Advisors Inc. raised its position in NuCana by 30.6% during the 4th quarter. Alps Advisors Inc. now owns 73,678 shares of the company’s stock worth $1,068,000 after purchasing an additional 17,259 shares during the last quarter. Partner Fund Management L.P. raised its position in NuCana by 14.9% during the 4th quarter. Partner Fund Management L.P. now owns 447,420 shares of the company’s stock worth $6,488,000 after purchasing an additional 58,062 shares during the last quarter. Rothschild Investment Corp IL bought a new position in NuCana during the 1st quarter worth $211,000. Asymmetry Capital Management L.P. raised its position in NuCana by 5.4% during the 1st quarter. Asymmetry Capital Management L.P. now owns 45,393 shares of the company’s stock worth $772,000 after purchasing an additional 2,346 shares during the last quarter. Finally, Marshall Wace North America L.P. raised its position in NuCana by 558.8% during the 1st quarter. Marshall Wace North America L.P. now owns 60,843 shares of the company’s stock worth $1,034,000 after purchasing an additional 51,607 shares during the last quarter. 38.03% of the stock is owned by institutional investors and hedge funds.
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.
Read More: What is the NASDAQ Stock Market?
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.